Advent Access completes CE Mark submission for av-Guardian™ , 2018
Advent Access is pleased to announce that our av-Guardian implant technology has completed regulatory submission and key audits for the CE Mark. The clinical trial results used in this submission had also been accepted to be presented at a renowned scientific conference later this year. This is an exciting milestone for us as it represents an important step towards commercialising the av-Guardian and unlocking the future of dialysis in novel or alternative care environments.
